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Abstract 
Objective 
To compare two approaches for trial teams to apply PRECIS-2 to pragmatic trials: independent 
scoring and scoring following a group discussion.  
Study Design and Setting 
We recruited multidisciplinary teams who were conducting or had conducted trials in primary care in 
collaboration with the Pragmatic Clinical Trials Unit, Queen Mary University of London. Each team 
carried out two rounds of scoring on the 9 PRECIS-2 domains: first independently using an online 
version of PRECIS-2 and secondly following a discussion. 
Results 
Seven teams took part in the study. Prior to the discussion within-team agreement in scores was 
generally poor and not all raters were able to score all domains; agreement improved following the 
discussion. The PRECIS-2 wheels suggested that the trials were pragmatic, though some domains 
were more pragmatic than others. 
 
Conclusion 
PRECIS-2 can facilitate information exchange within trial teams. To apply PRECIS-2 successfully we 
recommend a discussion between those with detailed understanding of: what usual care is for the 
intervention, the trial’s design including operational and technical aspects, and the PRECIS-2 
domains. For some cluster randomised trials greater insight may be gained by plotting two PRECIS-2 
wheels, one at the individual participant level and one at the cluster level. 
Key Words: Randomized controlled trials; Clinical trial methodology; Pragmatic trial; primary care; 
Trial design. 
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What is new? 
• PRECIS-2 offers a new tool for trial teams to exchange information and knowledge about  
trial design. 
• To score each PRECIS-2 domain successfully understanding is required of what usual care 
would be for the intervention, what is planned for the trial, and the interpretation of each 
domain in the context of the trial; a discussion amongst a multidisciplinary group may be 
required to score each domain. 
• The trials included in this study were broadly pragmatic, areas where they were commonly 
less pragmatic were recruitment, and organisation (the level of resources used to deliver 
the intervention). 
• When applying PRECIS-2 to cluster randomised trials greater insight may sometimes be 
gained by plotting two wheels, one at the level of the cluster and another at the level of 
individual participants 
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Background 
Many randomised controlled trials (RCTs) are carried out with the aim of informing health 
professionals, patients and policy makers about whether or not an intervention should be adopted 
in practice. To facilitate this it is recommended that trials taking a pragmatic design approach are 
carried out, testing the intervention under conditions as similar as possible to the conditions that 
would pertain if the intervention was rolled out in routine care (1-6).  It may be that the intervention 
itself alters or replaces some aspects of usual care, but the principle remains that if the purpose of 
the trial is to directly inform clinical practice, aside from the intervention itself, other aspects of care 
should be as they usually would be in the real world. For brevity we refer to these types of 
conditions as “usual care”. Recently there has been a growing interest in the benefits from more 
pragmatic designs. This has led to the publication of literature on how to design and conduct 
pragmatic trials (7-11), the latest of these developments, PRECIS-2 allows researchers to plot a graph 
illustrating whether their design is more or less pragmatic across a number of domains.  
PRECIS-2 is an updated version of PRECIS (9) with significant changes including revisions to the 
domains, the addition of a Likert scoring scale and a website which can be used to support use of the 
tool (https://precis-2.org). PRECIS-2 (Figure 1) has nine domains covering different aspects of a trial: 
eligibility, recruitment, setting, organisation, flexibility of delivery, flexibility of adherence, follow-up, 
primary outcome and primary analysis (12). To apply PRECIS-2 each domain is scored from one to 
five - a score of one indicates an explanatory design with highly controlled or ideal conditions for the 
intervention and a score of five indicates a very pragmatic design, replicating usual care conditions 
for that domain. The tool was developed to be used at the design stage so that if the tool highlights 
that a trial design does not match the investigators’ aims, they may choose to modify the design or 
reasons for the design may become more transparent. The tool can, however, also be used 
retrospectively as part as a critical appraisal of the generalisability of results from a trial or to 
illustrate a trial design to those using results.  
Investigators who used the original PRECIS either discussed PRECIS wheels as a group to come to 
some consensus (13-18) or used independent scoring by different team members (19-21). Challenges 
in applying the tool were reported both by investigators who discussed PRECIS wheels and those 
that did not hold a discussion. The approach we used to apply PRECIS-2 was informed by this work 
(13-21). In the earlier studies applying the original PRECIS, the tool was applied both in the design 
phase, as the authors intended PRECIS to be used, and also to trials which were already completed.  
Likewise, in work described here we consider trials at all stages in design.   
Our primary aim in this work was to inform investigators how best to use the tool regardless of 
whether it was to be used for design or retrospectively. We were particularly interested in doing so 
for trials at the pragmatic end of the pragmatic-explanatory spectrum for which PRECIS-2 was 
designed, and in exploring the difference between using the tool with and without discussion 
between group members.  
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Version 4.0  15/02/2017 
 
Page  5 of 13 
 
>> insert Figure 1: A blank PRECIS-2 Wheel*.<< 
*Reproduced with permission from (12)  
 
Methods 
We invited trial teams carrying out trials in collaboration with the Pragmatic Clinical Trials Unit 
(PCTU) at Queen Mary University of London to partake in this study. To identify trials at the 
pragmatic end of the pragmatic-explanatory spectrum we focused on trials in primary care 
(generally considered more pragmatic than trials in other settings (22)). .  We invited all trial teams 
that had recently completed their trial, were in the process of running their trial or were working 
towards submitting new proposals for funding.  
Challenges encountered applying the original PRECIS tool came from a lack of information or 
difference in interpretation across three areas: what is happening or is being planned for a trial (15); 
what usual care would be if the intervention were to be implemented in practice (16); and how to 
interpret the PRECIS domains in the context of the trial (18). Researchers also found a bias towards 
raters scoring their own trial as more pragmatic (18). To overcome these problems we selected 
different raters including the trial chief investigator, who had both clinical expertise of usual practice 
and the trial design, and the trial manager and statistician, who had detailed information about the 
technical and operational aspects of the trial design, conduct, and analysis. In addition we sought 
two independent views of the design: a member of the relevant trial steering committee plus one of 
the authors of this study (GF). GF had understanding of the PRECIS-2 domains, gained from 
discussions with two of the authors of PRECIS-2 (KL, ST). For trials which were in the design stage not 
all these positions had been appointed so we included instead co-applicants on the trial grants with 
appropriate experience. 
For each trial we asked the raters to independently score the trial using PRECIS-2 on two separate 
occasions: firstly pre-discussion using the online tool (www.PRECIS-2.org) and the information 
contained on the PRECIS-2 website and, secondly, post-discussion scoring following a group 
discussion of raters involved in the relevant trial. This discussion lasted up to two hours. PRECIS-2 
scores were plotted using the median of the scores for all of the raters for each trial. The group 
discussion was based on pre-discussion scores and structured around the three key areas identified 
from work on PRECIS: the interpretation of each PRECIS-2 domain, what usual care was for the trial 
and what was planned or had happened in the trial in relation to each domain; the discussion aimed 
achieve consensus on these three areas. However, the discussion would move on if there were areas 
of disagreement that could not be addressed within the time available. The post-discussion scores 
were made independently at the end of the meeting. 
We report the median of the pre-discussion and post-discussion scores for each domain and each 
trial as well as plotting PRECIS-2 wheels displaying the median pre-discussion and post-discussion 
scores. To assess the level of agreement within trial teams from the two sets of scores (pre-
discussion and post-discussion), we compare the range of the scores for each domain across raters 
for each trial. For each domain we report the median and interquartile range (IQR) of the ranges.  
Ethical approval for this study was granted by the Queen Mary Research Ethics Committee 
(reference QMREC1360d). The members of the trials teams involved in this study provided informed 
consent.  
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>> insert Figure 2: PRECIS-2 wheels for trials included in the study. The solid shapes indicate the 
median post discussion scores. Dashed lines show the median pre-discussion scores. << 
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Results 
We invited 10 trial teams working on trials supported by the PCTU to participate in the study and 
seven agreed to take part. The three trials that declined to take part all did so due to lack of 
availability of the trial team during the study period. The seven trials are described in table 1. All 
seven trials aimed to answer the question of whether the intervention of interest would work in 
practice and the chief investigators considered their designs to be pragmatic.   
The PRECIS-2 wheels (figure 2) indicate that trials being carried out by the PCTU are generally 
pragmatic. Domains for which trials were most often less pragmatic were Recruitment where four 
trials had post-discussion scores of three or less and Organisation where four trials had scores of 
three or less. All of the trials with less pragmatic scores for Recruitment were individually 
randomised, the cluster randomised trials were more pragmatic in their recruitment. 
We produced eight PRECIS-2 wheels (figure 2) for the seven trials included in the study. For STOP, 
one of the cluster randomised trials, during the discussion the trial team thought that it would help 
them understand their design more if they produced two sets of scores, one set at the individual 
participant level and one at the cluster level for the pharmacy/pharmacist. For this trial, not all the 
domains were applicable at the individual level and this is reflected in the PRECIS-2 wheel by the 
domains with no score showing. This decision was consistent with the purpose of PRECIS-2 and 
description of its use by those who developed it (12), but was not deemed necessary by the rating 
teams for the other two cluster randomised trials.  
Small differences between the pre-discussion scores and post-discussion score were observed. 
Almost all the differences between the pre-discussion scores and post-discussion scores were one 
point or less (figure 2, table 2). Thus for the majority of trials, design discussion led, at most, to a 
refinement in the extent a domain was considered pragmatic or explanatory rather than a change 
from a trial being rated as more pragmatic to more explanatory or visa versa. The one exception to 
this was the STOP trial which was at an earlier stage of development than the other trials. In this trial  
larger changes between the pre and post discussion scores were observed. This was in part due to 
greater understanding of how planned design related to the PRECIS-2 domains gained from plotting 
PRECIS-2 wheels at the individual and cluster level, and in part due to some aspects of the design not 
being clear to all the raters pre-discussion. 
The median range of the pre-discussion scores was two or greater for five out of nine domains: 
Recruitment (median range 3), Organisation (median range 2), Flexibility of delivery (median range 
2), Flexibility of adherence (median range 2), and Follow-up (median range 2). This indicates poor 
agreement sometimes to the extent that raters disagreed about whether the trial was essentially 
pragmatic or essentially explanatory. Agreement in the post-discussion scores was good, for all 
domains the median range of scores was one or less: raters disagreed over the extent to which a 
domain was pragmatic or explanatory rather than whether the domain was pragmatic or 
explanatory.  
Not all raters were able to score every domain using the online tool either due to insufficient 
information in the trial documents or due to insufficient knowledge of usual care. This was 
particularly an issue for Flexibility of adherence (21% of raters unable to score), Flexibility of delivery 
(14%), and Organisation (11%) (table 3). 
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>>insert Table 1: Description of trials included in study<< 
 
>> insert Table 2: Median pre-discussion scores and post-discussion PRECIS-2 scores for each trial<< 
*Only one set of pre-discussion scores were made for STOP, combining both the cluster and patient levels of the trial.  
 
>>insert Table 3: Median and interquartile range of the range of pre and post discussion scores << 
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Discussion 
We produced PRECIS-2 wheels for seven pragmatic trials of interventions in primary care. Most 
domains for each trial were scored by the teams as pragmatic indicating that the designs were 
appropriate to answer questions about the effectiveness of the interventions. Two domains, 
Recruitment and Organisation stood out as being rated as less pragmatic across four of the seven 
trials. This indicated that steps to recruit in these trials could impact on the applicability of their 
results and that resources over and above those required for the intervention itself might be needed 
to ensure successful roll out of interventions. 
Two of the trials included in the study were at the design stage and there was the potential for 
changes to their design following the application of PRECIS-2. For one of these trials, TANDEM, the 
trial team made no changes following the application of the tool; the trial team were experienced in 
designing pragmatic trials and had already discussed the issues raised by applying PRECIS-2 prior to 
using the tool. The team commented that PRECIS-2 covered important areas of a trial’s design that 
researchers should be aware of but that experienced teams may not need to go through the process 
of applying it fully. For the second trial, STOP, the design was yet to be finalised at the time of 
writing and the team found that PRECIS-2 helped clarify their thinking about their design.  Of the 
completed trials, the researchers involved commented that the tool helped them think more about 
generalizability and had they applied it at the design stages could have pre-empted feedback they 
received from research funders on submitted applications.  
The group discussions lead to a refinement rather than large change in median PRECIS-2 scores for 
each trial with the exception of one trial. Prior to the discussion agreement in scores, as measured 
by the range in scores for each domain, was generally poor and some raters were unable to rate all 
domains. The domains Recruitment, Flexibility of adherence, Flexibility of delivery and Organisation 
posed the greatest challenges to the raters when scoring the trials independently. Following the 
discussion the agreement in scores improved and raters were able to score all domains. The 
challenges encountered by investigators applying the original PRECIS tool (9): lack of information or 
understanding about the trial, usual care, or the PRECIS-2 domains, were mostly overcome. It was 
often the case that not one person in the trial team would have full information to score all domains 
and good understanding came only through sharing information. This suggests that greater attention 
may need to be given to the reporting of operational aspects of trials if PRECIS-2 is to be applied by 
external groups. Updating the SPIRIT (26) and CONSORT (10, 27) reporting guidelines for trial 
protocols and RCTs, to include more focus on how interventions are delivered and the resources and 
expertise used, could help assessment of whether the results of trials are applicable to a particular 
setting.  
We identified one further challenge when applying PRECIS-2 to pragmatic trials in primary care. 
When an intervention significantly changed the way in which patients were treated it made 
comparisons with usual care difficult; especially for the Organisation domain, as it was not always 
clear what level of expertise or resourcing would be available to deliver the intervention if it were to 
be implemented in primary care post-trial.  For example, in the COPERS trial, the intervention was 
delivered partly by lay people specifically recruited to deliver the intervention. This made judging the 
level of expertise and resources that would be available to deliver the intervention in usual care 
difficult as it was unclear what resources would be made available in primary care practice to recruit 
and train these individuals were the intervention to be rolled out following the trial. 
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At the time of writing there has been one other published account of using PRECIS-2 in which 
Johnson et al (28) applied PRECIS-2 to five pragmatic, cluster randomised trials in health care 
systems research set in the USA producing one PRECIS-2 wheel for each trial. There are similarities 
with our findings in that there were challenges applying PRECIS-2 to interventions which changed 
usual care in a significant way and that not all the information required to apply PRECIS-2 was 
available in the trial documents. A notable difference in findings was that Johnson et al encountered 
more difficulties applying PRECIS-2 possibly because these authors did not report holding a 
discussion before scoring. Johnson et al also did not have access to the full PRECIS-2 publication at 
the time of scoring (12) and had no involvement from the authors of PRECIS-2 in clarifying the 
definitions of the PRECIS-2 domains.  Some of the trials in Johnson et al (28) may also have benefited 
from producing two PRECIS-2 wheels, one at the cluster level and one at the individual level. 
The results of this study are based on a sample of trials undertaken in a clinical trials unit that 
specialises in pragmatic trials so different findings may arise from a unit with less of an expertise in 
pragmatic trials. In particular there may be greater disagreement in scores made independently by 
researchers with less experience designing pragmatic trials as there could be greater scope for 
differences in the interpretation of the PRECIS-2 domains or what it means for a trial to be 
pragmatic. The focus of this study was pragmatic trials carried out in primary care; different 
challenges may present when applying PRECIS-2 to trials with more explanatory designs or in other 
healthcare settings.  
Conclusions 
Discussing PRECIS-2 wheels facilitated an exchange of information between different members of 
the trial team. It also highlighted two areas, recruitment and the level of resources used to deliver 
the intervention, where design decisions may be impacting the applicability of results of trials from 
the PCTU, and it focused discussions around generalisability. When considering cluster randomised 
trials or other more complex trial designs greater insight may be gained from plotting more than one 
PRECIS-2 wheel. To apply PRECIS-2 successfully we recommend holding a discussion between a 
group of people who between them have knowledge of what usual care is for the intervention, 
details of the trial’s design including operational and technical aspects and an understanding of the 
PRECIS-2 domains. 
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Table 1: Description of trials included in study 
Short 
Title  
Full Title Intervention & Setting Unit of 
Randomis
ation 
Status at 
time of 
study 
No. in rating 
group 
COPERS 
(23) 
Effectiveness and cost-effectiveness of a 
novel, group self-management course for 
adults with chronic musculoskeletal pain 
Group self-management course for chronic pain patients. 
Groups facilitated by a healthcare professional and lay person 
with experience of chronic pain. Trial set in local medical or 
community venues in urban and rural areas of the UK. 
Individual Complete 5 (CI, trial 
manager, TSC 
member, trial 
statistician, GF). 
HepFree Chronic viral hepatitis in first and second 
generation immigrants from ‘at risk’ 
countries. A controlled randomised cross 
sectional  cluster trial to assess the impact 
of  identifying, screening and treating 
immigrants with viral hepatitis 
Two interventions tested: 1) targeted screening for viral 
hepatitis for first and second generation immigrants from at 
risk countries 2) involvement of community therapy following 
diagnosis. Trial carried out across two cities in the UK with 
large immigrant populations (London & Bradford) 
GP Surgery Recruiting 5 ((CI, trial 
manager, TSC 
member, trial 
statistician, GF). 
Rhiva 2 
(24) 
Promotion of rapid testing for HIV in 
primary care: a cluster randomised trial 
Intervention involved an education programme promoting 
rapid HIV testing to adults newly registering at GP surgeries. 
Trial carried out in primary care settings in London, UK.  
GP Surgery Complete 4 (CI, trial 
manager, trial 
statistician, GF).. 
STOP Optimising pharmacist-based treatment 
from smoking cessation 
Educational intervention package delivered to pharmacy 
staff. Pharmacies recruited to trial from those offering NHS 
smoking cessation services in two London boroughs. 
Pharmacy Protocol 
writing 
4 (CI, co-
applicant, trial 
statistician, GF). 
SWAP A peer-support weight action programme to 
supplement brief advice in general practice 
Group health behaviour modification intervention providing 
participants with the tools to lose weight and maintain a 
healthy lifestyle including pedometer use. Groups delivered 
by two trained advisors in community settings in London, UK. 
Individual Recruiting 5 (CI, trial 
manager, TSC 
member, trial 
statistician, GF). 
Tandem  Tailored intervention for anxiety and 
depression Management in chronic 
obstructive pulmonary disease. 
Psychological intervention based on cognitive behavioural 
approach to proceed routine pulmonary rehabilitation. 
Delivered 1-1 by respiratory nurses or allied health 
professionals. Intervention delivered in participant’s home or 
convenient NHS facility. Trial run from sites across the UK. 
Individual Submitted 
for funding 
4 (3x co-
applicant, GF). 
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WAIT 
(25) 
Intermittent montelukast in children aged 
10 months to 5 years with wheeze: a 
multicentre, randomised, placebo-
controlled trial 
Intermittent Montelukast given by parents at every viral cold 
or wheezing episode. Patients recruited via primary and 
secondary care sites across the UK and intervention delivered 
at participant’s home. 
Individual Complete 5 (CI, trial 
manager, TSC 
member, trial 
statistician, GF). 
 
Table 2: Median pre-discussion scores and post-discussion PRECIS-2 scores for each trial 
 
COPERS HepFree Rhiva 2 
STOP 
Cluster 
STOP 
Patient 
SWAP TANDEM WAIT 
Pre Post Pre Post Pre Post Pre* Post Pre* Post Pre Post Pre Post Pre Post 
Eligibility 4.5 4 5 5 5 5 5 5 5 5 3 3 4 4 4 4 
Recruitment 4 3 4 4 4.5 5 3 4.3 3 5 3.5 3 3.5 2.5 3 3 
Setting 3 4 4.5 4 5 4 4.5 4.5 4.5 5 5 4 5 5 4 5 
Organisation 2.5 2 4 3 3 4 2.5 4 2.5 4.5 4 3 2 2 5 5 
Flexibility of delivery 3.5 4 3 4 4 4 2 4 2 
 
4 4 2 2 4 4.5 
Flexibility of adherence 5 5 5 4 4 4 1 5 1 5 4.5 4 5 3.5 4 3 
Follow up 4 4 4.5 4 4.5 5 2 5 2 3 3 2 4 4 2 1 
Primary outcome 4 4 4 5 4.5 5 5 3.5 5 
 
4.5 4 5 5 5 5 
Primary analysis 5 5 5 5 5 5 5 5 5 
 
5 5 5 5 5 5 
*Only one set of pre-discussion scores were made for STOP, combining both the cluster and patient levels of the trial.  
 
Table 3: Median and interquartile range of the range of pre and post discussion scores  
Domain 
Range of pre-discussion 
scores, 
Range of post-
discussion scores,  
Raters unable to score 
domain pre-discussion, 
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 median (interquartile 
range) 
median (interquartile 
range) 
n (%) 
Eligibility 1 (0, 2) 0 (0, .5) 1 (4%)  
Recruitment 3 (2, 4) 1 (0, 1) 0 (0%)  
Setting 1 (0, 2) 1 (.5, 1) 1 (4%)  
Organisation 2 (2, 2) 1 (1, 1) 3 (11%)  
Flexibility of delivery 2 (1, 4) 1 (0, 1) 4 (14%)  
Flexibility of adherence 2 (0, 3) 0.5 (0, 1.5) 6 (21%)  
Follow up 2 (1, 3) 0 (0, 1.5) 0 (0%)  
Primary outcome 1 (0, 2) 1 (0, 2) 0 (0%)  
Primary analysis 0 (0, 1) 0 (0, 0) 1 (4%)  
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Figure 1: A blank PRECIS-2 Wheel*. 
 
*Reproduced with permission from (12)  
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Figure 2: PRECIS-2 wheels for trials included in the study. The solid shapes indicate the median post 
discussion scores. Dashed lines show the median pre-discussion scores.
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Applying PRECIS-2 to pragmatic trials in 
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What is new? 
• PRECIS-2 offers a new tool for trial teams to exchange information and knowledge about  
trial design. 
• To score each PRECIS-2 domain successfully understanding is required of what usual care 
would be for the intervention, what is planned for the trial, and the interpretation of 
each domain in the context of the trial; a discussion amongst a multidisciplinary group 
may be required to score each domain. 
• The trials included in this study were broadly pragmatic, areas where they were 
commonly less pragmatic were recruitment, and organisation (the level of resources 
used to deliver the intervention). 
• When applying PRECIS-2 to cluster randomised trials greater insight may sometimes be 
gained by plotting two wheels, one at the level of the cluster and another at the level of 
individual participants 
